Development of fluorizoline analogues as prohibitin ligands that modulate C-RAF signaling, p21 expression and
Nora Chouha1, Hussein Abou-Hamdan2, Hajime Yurugi3
1Regenerative Nanomedicine (UMR 1260), INSERM, University of Strasbourg, Center of Research in Biomedicine of Strasbourg, 1 Rue Eugène Boeckel, 67000, Strasbourg, France; Laboratory of Chemistry and Environmental Chemistry (LCCE), Department of Chemistry, Faculty of Sciences, Batna-1 University, Batna, Algeria.
Abstract:
Fluorizoline is a cytotoxic trifluorothiazoline that targets the scaffold proteins prohibitins-1 and -2 (PHB1/2) to inhibit the kinase C-RAF and promote the expression of the cyclin-dependent kinase inhibitor p21 to induce cancer cell death. In melanocytes, fluorizoline also induces the synthesis of melanin. Herein we report the first structural requirement of fluorizoline analogues for these activities. We identified in particular some compounds that display enhanced anti-C-RAF and anti-MEK activities, and a higher cytotoxicity in HeLa cells compared to fluorizoline. These results provide a foundation for further optimization of PHB ligands for the treatment of cancers. We also discovered an analogue of fluorizoline that displays pharmacological effects opposed to those of fluorizoline and that can be used as a chemical tool to explore PHB signaling in cancers and other diseases.
Insights
Researchers explored fluorizoline analogues, discovering compounds with enhanced anti-cancer activity by targeting prohibitin proteins (PHB1/2). These findings pave the way for new cancer treatments and tools to study PHB signaling.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Cancer Research
Background:
- Fluorizoline is a cytotoxic trifluorothiazoline targeting prohibitin proteins (PHB1/2).
- It inhibits C-RAF kinase, upregulates p21, and induces cancer cell death.
- Fluorizoline also affects melanin synthesis in melanocytes.
Purpose of the Study:
- To determine the structural requirements of fluorizoline analogues for their biological activities.
- To identify novel compounds with improved anti-cancer properties.
- To develop chemical tools for exploring prohibitin signaling.
Main Methods:
- Synthesis and evaluation of fluorizoline analogues.
- Assays for anti-C-RAF and anti-MEK kinase activity.
- Cytotoxicity assays in cancer cell lines (HeLa).
Main Results:
- Identified fluorizoline analogues with enhanced anti-C-RAF and anti-MEK activities.
- Some analogues exhibited superior cytotoxicity in HeLa cells compared to fluorizoline.
- Discovered an analogue with opposing pharmacological effects, useful as a chemical probe.
Conclusions:
- Established the structural basis for fluorizoline's activity on PHB1/2, C-RAF, and p21.
- Developed potent fluorizoline derivatives for potential cancer therapy.
- Provided a novel chemical tool for investigating prohibitin signaling in diseases.
